-
-
-
-
-
-
-
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) to Acquire Turning Point Therapeutics (TPTX) for $76 Per Share
-
-
-
-
-
-
-
Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors
-
-
-
-
-
-
-
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China
-
-
-
-
-
-
-
Turning Point Therapeutics,Inc. (TPTX) Appoints Patrick Machado J.D. to Board
-
-
1,155,355 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

